基因编辑权威指南。
★
菜单
首页 学习 新闻
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

专家观点
你已经了解生物学基础,只需内容本身,简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式
Two empty chairs facing each other with a balance scale above

CRISPR Decoded

Ethics

The arguments this technology forces, presented with the strongest case on each side, not a verdict.

8 ethics in CRISPR Decoded. Each topic shows the strongest argument on both sides before you open it. CRISPR Decoded does not take a position.

8 已显示

Germline and heritable genome editing

Editing embryos, eggs or sperm would change every cell of a future person and be passed to their descendants, which is why it is…

Proponents argue

For couples where both partners carry two copies of a recessive disease variant, no embryo can be free of it. Preimplantation selection cannot help, and…

Critics argue

Consent is impossible: the person most affected does not exist yet and their descendants never will be asked.

5 本页面已摘要的司法管辖区

Enhancement and 'designer babies'

The question of editing for traits rather than disease, where the science is much weaker than the debate assumes.

Proponents argue

Parents already shape children's traits through education, nutrition, medicine and environment; genetic means are not obviously different in kind.

Critics argue

The polygenic reality means promised enhancements are largely unachievable, so the debate risks legitimising claims that cannot be delivered.

Disability, difference and what counts as a disease

Whether some conditions gene editing could eliminate are diseases to be treated or forms of human variation: a question the…

Proponents argue

Many conditions cause severe pain, organ damage and early death; treating them is not a statement about anyone's worth.

Critics argue

Resources directed at eliminating a condition are not directed at accommodating the people who have it.

Access, cost and global equity

A two-million-dollar one-time treatment for a disease concentrated in the world's poorest regions is the field's most concrete…

Proponents argue

High prices fund the development that produced the therapy, and no therapy is worse than an expensive one.

Critics argue

Pricing at what health systems will bear rather than what treatment costs makes universal access structurally impossible.

Gene drives and the environment

Engineered genetic elements designed to spread through a wild population: potentially eliminating malaria, and potentially…

Proponents argue

Malaria kills hundreds of thousands of people a year, most of them children under five; existing tools have plateaued and resistance is rising.

Critics argue

An organism engineered to spread cannot meaningfully be recalled once released.

3 本页面已摘要的司法管辖区

Biosecurity and dual use

Techniques that make medicine cheaper and faster also make misuse cheaper and faster: the unavoidable dual-use problem.

Proponents argue

Open publication accelerates defensive work on vaccines, diagnostics and therapeutics more than it aids attack.

Critics argue

Some results genuinely lower the barrier to causing harm, and publishing them is a choice.

Consent for permanent change

What informed consent means for a treatment that cannot be stopped, reversed or withdrawn.

Proponents argue

Patients with severe disease are capable of weighing serious risk and are entitled to do so.

Critics argue

'Informed' is hard to achieve when the mechanism is unfamiliar and long-term effects are unknown even to investigators.

Human embryo research

Editing embryos in the laboratory, without transfer to a uterus, is permitted in some countries and prohibited in others, and it…

Proponents argue

It is the only way to understand early human development and why so many pregnancies fail.

Critics argue

Some hold that an embryo has moral status making research use impermissible regardless of benefit.

4 本页面已摘要的司法管辖区